[Coagulopathy in COVID-19: pathophysiology]

G Ital Cardiol (Rome). 2020 Jul;21(7):483-488. doi: 10.1714/3386.33633.
[Article in Italian]

Abstract

On March 11, 2020, just after 2 months from the first cases of coronavirus disease 2019 (COVID-19) in China, the Director-General of the World Health Organization stated that COVID-19 has to be considered as a pandemic. Italian doctors were the first protagonists, after the Chinese ones, in the management of this disease. Clinical observations showed that, in addition to the respiratory infection, a systemic inflammatory response occurs, which leads to coagulation disorders and consequent venous thromboembolism as well as other thrombotic complications. We here review the available literature on this issue to better understand the pathophysiological mechanisms of coagulopathy useful to draw future clinical and therapeutic conclusions.

Publication types

  • Review

MeSH terms

  • Anticoagulants / therapeutic use
  • Blood Coagulation Disorders / drug therapy
  • Blood Coagulation Disorders / epidemiology*
  • Blood Coagulation Disorders / physiopathology
  • COVID-19
  • Cause of Death
  • Comorbidity
  • Coronavirus Infections / diagnosis
  • Coronavirus Infections / epidemiology*
  • Female
  • Humans
  • Incidence
  • Italy
  • Male
  • Pandemics / statistics & numerical data*
  • Pneumonia, Viral / diagnosis
  • Pneumonia, Viral / epidemiology*
  • Risk Assessment
  • Survival Analysis
  • Venous Thromboembolism / diagnosis
  • Venous Thromboembolism / drug therapy
  • Venous Thromboembolism / epidemiology*
  • Viremia / diagnosis
  • Viremia / epidemiology*
  • World Health Organization

Substances

  • Anticoagulants